Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × IPI-549 × Clear all
NCT03719326 2024-05-24

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
35 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡